

Bölüm 3

TİROİD KANSERLERİ EPİDEMİYOLOJİSİ

Nergis KAYACAN¹

GİRİŞ

Tiroid kanseri, tiroid bezinden köken alan malign neoplazmları ifade eder ve endokrin sistem tümörleri arasında en sık görülen malignitelerdir (1). Son yıllarda tiroid kanserlerinin insidansında belirgin bir artış gözlenmiştir. Bu artış büyük oranda, görüntüleme tekniklerindeki gelişmelere bağlanmakla birlikte, yürütülen tarama politikaları sonucu küçük, klinik olarak anlamlı olmayan lezyonların daha sık tespit edilmesi, çevresel maruziyetler ve genetik faktörlerin de rol oynadığı düşünülmektedir (2).

GÖRÜLME SIKLIĞI VE DAĞILIMI

Tiroid kanseri, endokrin sistemin malignitelerinin en sık görülenidir ve %90'ından fazlasını oluşturur. Tüm kanserlerin ise yaklaşık %1'ini tiroid maligniteleri oluşturmaktadır (2). Dünya genelinde yıllık insidansı 100.000 kişide 3 ila 10 arasında değişmektedir (3).

2012 yılı GLOBOCAN (Global Cancer Observatory) verilerine bakıldığında dünya çapında yaklaşık 298.000 yeni tiroid kanseri vakası bildirilmiştir (4). 2020 yılı itibarıyla bu sayı 586.000'e ulaşmıştır. 2022 GLOBOCAN verilerine göre ise dünya genelinde 821.214 yeni tiroid kanseri vakası ve tiroid kanserlerine bağlı 47.507 ölüm bildirilmiştir (5). Bu verilere göre tiroid kanseri dünyada en yaygın 9. kanser türü haline gelmiştir (6).

¹ Dr. Öğr. Üyesi, Bandırma Onyedi Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı AD.,
nkayacan@bandirma.edu.tr, ORCID iD: 0000-0003-1922-5835

DOI: 10.37609/akya.72.c631

KAYNAKLAR

1. Davies L., Welch H. G. Increasing incidence of thyroid cancer in the United States, 1973-2002. *Jama*, 2006; 295(18), 2164-2167.
2. Vaccarella S., Franceschi S., Bray F., Wild C. P., Plummer M., & Dal Maso, L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. *The New England Journal of Medicine*, 2016; 375(7), 614-617.
3. Morgan E., Arnold M., Gini A., Lorenzoni V., Cabaasag C. J., Laversanne M., ... & Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. *Gut*, 2023; 72(2), 338-344.
4. Torre L. A., Siegel R. L., Ward E. M., & Jemal A. Global cancer incidence and mortality rates and trends an update. *Cancer epidemiology, biomarkers & prevention*, 2016; 25(1), 16-27.
5. Lyu, Z., Zhang, Y., Sheng, C., Huang, Y., Zhang, Q., & Chen, K. Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN. *Chinese Medical Journal*, 2024; 137(21), 2567-2576.
6. Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal, A., & Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 2021; 71(3), 209-249.
7. Ferlay J., Colombet M., Soerjomataram I., Parkin D. M., Piñeros M., Znaor A., & Bray F. (2021). Cancer statistics for the year 2020: An overview. *International journal of cancer*, 149(4), 778-789.
8. Kitahara C. M., Platz E. A., Freeman L. E. B., Hsing A. W., Linet M. S., Park Y., ... & Berrington de González, A. Obesity and thyroid cancer risk among US men and women: a pooled analysis of five prospective studies. *Cancer epidemiology, biomarkers & prevention*, 2011; 20(3), 464-472.
9. Stathori G., Hatziagapiou K., Mastorakos G., Vlahos N. F., Charmandari E., & Valsamakis G. (2024). Endocrine-Disrupting Chemicals, Hypothalamic Inflammation and Reproductive Outcomes: A Review of the Literature. *International Journal of Molecular Sciences*, 2024; 25(21), 11344.
10. Ahn H. S., Kim H. J., Welch H. G. Korea's thyroid-cancer "epidemic" screening and overdiagnosis. *New England Journal of Medicine*, 2014; 371(19), 1765-1767.
11. Rusiecki J. A., McAdam J., Denic-Roberts H., Sjodin A., Davis M., Jones R., ... & Zhang, Y. (2024). Organochlorine pesticides and risk of papillary thyroid cancer in US military personnel: a nested case-control study. *Environmental Health*, 2024; 23(1), 28.
12. Boas M., Main KM, Feldt-Rasmussen U. Environmental chemicals and thyroid function: an update. *Curr Opin Endocrinol Diabetes Obes* 2009; 16:385-91.
13. Türkiye Kanser İstatistikleri 2020, T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, Ankara, 2025
14. Sahin S. B., Yucel A. F., Gucer H., Pergel, A., Bedir R., Aydin I., ... & Sahin, O. Z. Distribution of thyroid cancer in the eastern part of Turkey 27 years after the chernobyl accident. *World Journal of Oncology*, 2014; 4(6), 230.
15. Acar H., Çakabay B., Bayrak, F., Evrenkaya T. Effects of the Chernobyl disaster on thyroid cancer incidence in Turkey after 22 Years. *International Scholarly Research Notices*, 2011(1), 257943.
16. Türkmen, A. (2022). Tiroid cerrahisi ve perioperatif hemşirelik bakimi. *Selçuk Sağlık Dergisi*, 2022; 3(2), 180-191.
17. Williams D. Radiation carcinogenesis: lessons from Chernobyl. *Oncogene*, 2008; 27(2), S9-S18.
18. Ito, Y., Miyauchi, A., & Oda, H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. *European Journal of Surgical Oncology*, 2018; 44(3), 307-315.
19. Wells Jr S. A., Asa S. L., Dralle H., Elisei R., Evans D. B., Gagel R. F., ... & Waguespack, S. G. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. *Thyroid*, 2015; 25(6), 567-610.
20. Ron E., Lubin J. H., Shore R. E., Mabuchi K., Modan B., Pottern L. M., ... & Boice Jr J. D. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiation research*, 2012; 178(2), AV43-AV60.
21. Romei C. Elisei R. (2021). A narrative review of genetic alterations in primary thyroid epithelial cancer. *International journal of molecular sciences*, 2021; 22(4), 1726.
22. Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. Integrated genomic analysis of Hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. *Cancer Cell* 2018; 34:256-270
23. Travaglino A., Pace M., Varricchio S., Insabato L., Giordano C., Picardi M., ... & Mascolo, M. Hashimoto thyroiditis in primary thyroid non-Hodgkin lymphoma: a systematic review and meta-analysis. *American journal of clinical pathology*, 2020; 153(2), 156-164.

24. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Annals of internal medicine*. 1997; 126:226-231.
25. Fisher SB, Perrier ND. The incidental thyroid nodule. *CA: a cancer journal for clinicians*. 2018; 68:97-105.
26. Inskip P. D. Thyroid cancer after radiotherapy for childhood cancer. *Medical and Pediatric Oncology: The Official Journal of SIOP—International Society of Pediatric Oncology (Société Internationale d'Oncologie Pédiatrique)*, 2001;36(5), 568-573.
27. Cardis E., Kesminiene A., Ivanov V., Malakhova I., Shibata Y., Khrouch V., ... & Williams D. Risk of thyroid cancer after exposure to 131 I in childhood. *Journal of the National Cancer Institute*, 2005; 97(10), 724-732.
28. Meydanlioğlu A. M. A. Sağlık Çalışanlarının Sağlık ve Güvenliği. *Balıkesir Sağlık Bilimleri Dergisi*, 2013;2(3), 192-199.
29. Shore R. E. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. *Radiation research*, 1992;131(1), 98-111.
30. Tronko M., Shpak V., Bogdanova T., Saenko V., Yamashita S. [Chapter 3] Epidemiology of thyroid cancer in Ukraine after Chernobyl. *Thyroid Cancer In Ukraine After Chernobyl dosimetry, epidemiology, pathology, molecular biology*, 2014;39-64.
31. Yasumura S., Hosoya M., Yamashita S., Kamiya K., Abe M., Akashi M., ... & Ozasa K. Study protocol for the Fukushima health management survey. *Journal of epidemiology*, 2012; 22(5), 375-383.
32. Zanzonico P. Nuclear medicine physics. *Medical physics*, 2011; 38(8), 4904.
33. Pellegriti G., Frasca F., Regalbuto C., Squatrito S., Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. *Journal of cancer epidemiology*, 2013(1), 965212.
34. Rahbari R., Zhang L., Kebebew E. Thyroid cancer gender disparity. *Future oncology*, 2010;6 (11), 1771-1779.
35. Yane K., Kitahori Y., Konishi N., Okaichi K., Ohnishi T., Miyahara H., ... & Hiasa, Y. Expression of the estrogen receptor in human thyroid neoplasms. *Cancer letters*, 1994; 84(1), 59-66.
36. Sa H. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. *Cancer*, 1998; 83, 2638-2648.
37. Byrd D. R., Brookland R. K., Washington M. K., Gershenwald J. E., Compton C. C., Hess K. R., ... & Meyer, L. R. *AJCC cancer staging manual (Vol. 1024)*. M. B. Amin, S. B. Edge, & F. L. Greene (Eds.). 2017; New York
38. Boelaert K. The association between serum TSH concentration and thyroid cancer. *Endocrine-related cancer*, 2009;16(4), 1065-1072.
39. Moosa M., Mazzaferri, E. L. Outcome of differentiated thyroid cancer diagnosed in pregnant women. *The Journal of Clinical Endocrinology & Metabolism*, 1997;82(9), 2862-2866.
40. Lacey Jr, J. V., Brinton L. A., Lubin J. H., Sherman M. E., Schatzkin A., Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. *Cancer Epidemiology Biomarkers & Prevention*, 2005; 14(7), 1724-1731.
41. Machens A., Hauptmann S., Dralle H. Disparities between male and female patients with thyroid cancers: sex difference or gender divide?. *Clinical endocrinology*, 2006;65(4), 500-505.
42. Şimşek T., Cantürk N. Z. Tiroid Karsinomlarının Genetik Temeli: Bir Derleme. *Okmeydanı Tıp Dergisi*, 2013;29(1), 1-7.
43. Ji Q., Wu Y., Zhu Y., Wang Y., Zhang R., Luo, Z. Familial papillary thyroid carcinoma. *Zhonghua wai ke za zhi [Chinese Journal of Surgery]*, 2002;40(8), 564-566.
44. Wells Jr, S. A., Asa S. L., Dralle H., Elisei R., Evans D. B., Gagel R. F., ... & Waguespack, S. G. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. *Thyroid*, 2015;25(6), 567-610.
45. ML Brandi. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab*, 2001; 86: 5658-5671.
46. Zimmermann M. B., Boelaert K. Iodine deficiency and thyroid disorders. *The lancet Diabetes & endocrinology*, 2015; 3(4), 286-295.
47. Zhu G. A high iodine intake, thyroid diseases and the prevalence of papillary carcinoma (PTC). *Cancer Report and Review*, 2017;2(2), 1-9.
48. WHO, UNICEF, ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers. Geneva: World Health Organization, 2007, 1-94.
49. Fernandes G. A., de Matos L. L., Dedivitis R. A. Risk factors for malignancy in patients with multinodular goiter. *International Archives of Otorhinolaryngology*, 2023;27(01), e138-e142.
50. Gharib H., Papini E. Thyroid nodules: clinical importance, assessment, and treatment. *Endocrinology and metabolism clinics of North America*, 2007;36(3), 707-735.

51. Singh B., Shaha A. R., Trivedi H., Carew J. F., Poluri A., Shah J. P. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. *Surgery*, 1999;126(6), 1070-1077.
52. Streetman D. D., Khanderia U. Diagnosis and treatment of Graves disease. *Annals of Pharmacotherapy*, 2003;37(7-8), 1100-1109.
53. Schmid D., Ricci C., Behrens G, Leitzmann M. F. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. *Obesity reviews*, 2015;16(12), 1042-1054.
54. Cheng S. P., Yin P. H., Hsu Y. C., Chang Y. C., Huang S. Y., Lee J. J., Chi C. W. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. *Oncology reports*, 2011;26(5), 1265-1271.
55. Li L. R., Song J. L., Liu H. Q., Chen C. (2023). Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism. *Discover Oncology*, 2023;14(1), 23.
56. Bertelsen J. B., Hegedüs L. Cigarette smoking and the thyroid. *Thyroid*, 1994;4(3), 327-331.
57. Mack W. J., Preston-Martin S., Bernstein L., Qian, D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. *Annals of epidemiology*, 2002; 12(6), 395-401.
58. Hong S. H., Myung S. K., Kim H. S. Alcohol intake and risk of thyroid cancer: a meta-analysis of observational studies. *Cancer Research and Treatment: Official Journal of Korean Cancer Association*, 2017;49(2), 534-547.
59. Ullmann T. M., Gray K. D., Limberg J., Stefanova D., Moore M. D., Buicko J., ... & Beninato T. Insurance status is associated with extent of treatment for patients with papillary thyroid carcinoma. *Thyroid*, 2019;29(12), 1784-1791.